FBIS4-51042 "drchi101_b_94004" FBIS-CHI-94-101 Daily Report 25 May 1994 United States & Canada American Pharmaceutical Plant Profits From Chinese Market American Pharmaceutical Plant Profits From Chinese Market OW2505091494 Beijing XINHUA in English 0710 GMT 25 May 94 OW2505091494 Beijing XINHUA English BFN [Text] Tianjin, May 25 (XINHUA) -- Smith Kline, the fifth largest American pharmaceuticals and medical products company, has invested four million U.S. dollars in Tianjin ten years ago and had made a total of 460 million yuan (about 50 million U.S. dollars) in profits by the end of last year. As China's second-largest pharmaceutical enterprise, the Tianjin Smith Kline Pharmaceuticals Co., Ltd. is expected to record another 670 million yuan in sales this year. Occupying seven ha of land in the eastern suburbs of the north China port city of Tianjin, the Sino-U.S. joint venture is composed of a preparation plant and a raw materials plant. The highway linking Tianjin with the factory was built specially by Tianjin municipality for the enterprise. With advanced technology from the American pharmaceutical giant, the venture has developed several products which have become household names across China, doubling its sales volume since 1990. So far, the joint venture has established over 100 sales offices in 25 provinces and municipalities across China. Most of the sales representatives have received special training from the American company. "Our unique method in sales is one of the most important reasons for our success," said Zhang Zhi, deputy general manager of the company, adding that the enormous Chinese market has proved ideal for the method. According to Zhang, the company will put a series of new products onto the Chinese market this year so as to maintain its competitiveness here.
